Patients

25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia
News

25th EHA Annual Virtual Congress: TIF Brings you All the Latest Developments on Thalassaemia

TIF was excited to participate in the 25th European Hematology Association (EHA) Annual  Virtual Congress, held this year virtually on 11 – 21 June 2020. Dr Androulla Eleftheriou (TIF Executive…
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America
News

COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America

On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a fruitful discussion with patient advocates from the AMRO region about…
COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients
News

COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients

An Expert Panel of Six Medical Professionals from various countries, such as India, the UK, Italy and Saudi Arabia, shared their experiences with TIF on the impact of the COVID-19…
TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients
News

TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients

See what patients from various countries across the world who successfully took TIF’s Thal e-Course, the ultimate self-paced, interactive, online Εducational Course for individuals with thalassaemia and their families, have to say…
WORLD BLOOD DONOR DAY 2020: Give blood and make the world a healthier place
EventsMember NewsPatientsTIF NewsWorld Blood Donor Day

WORLD BLOOD DONOR DAY 2020: Give blood and make the world a healthier place

Safe blood saves lives This year, World Blood Donor Day will once again be celebrated around the world on 14 June and TIF will be joining them! The event serves to…
FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Clinical News

FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…
Explaining Gene Therapy in thalassaemia (2020)
Publications

Explaining Gene Therapy in thalassaemia (2020)

The second educational brochure from the TIF’s ‚Gene Therapy‘ booklet series, providing an in-depth view of how this revolutionary therapy works in patients with β-thalassaemia major.
TIF Issues Position Statement in Honour of the World Blood Donor Day 2020
News

TIF Issues Position Statement in Honour of the World Blood Donor Day 2020

There is one thing that definitely makes us heroes: giving blood.  It is a life-saving gesture that any of us in good health should very seriously consider making. Every couple…
Prevention of Inherited Diseases – The Example of β-Thalassaemia (2020)
TIF Publications

Prevention of Inherited Diseases – The Example of β-Thalassaemia (2020)

An educational brochure explaining the inheritance patterns of β-thalassaemia and the choices available for an “at-risk“ couple to have a child without the disease.
JUST LANDED: The “Prevention of Inherited Diseases – The Example of β-Thalassaemi“ Educational Brochure by TIF
News

JUST LANDED: The “Prevention of Inherited Diseases – The Example of β-Thalassaemi“ Educational Brochure by TIF

Prevention is the only measure that can drastically reduce the incidencies of severe haemoglobin disorders, such as β-thalassaemia. It is also what allowed countries like Greece, Italy and Cyprus to go from…
Back to top button
Close
Close